Beta Bionics, Inc.

NASDAQ:BBNX

Medical - Equipment & Services

Healthcare
$14.33 +3.18%

+$0.42 today

Market cap
$644.70M
Beta
3.39
P/E (TTM)
-9.1
EPS (TTM)
-$1.50
52W Low $8.80High $32.71

Volume 1.38M

Average 0.99M

BBNX Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Beta Bionics, Inc.NASDAQ: BBNX

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash turns negative

Q1 FY2026 net change in cash was -$1.37M, compared with $12.02M a year earlier. Trailing-twelve-month net change in cash was -$12.25M.

Context

  • Net change in cash amounted to 1.1% of revenue in FY2025, down 4.8 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly net change in cash holds near -$1.37M or moves back toward the trailing-twelve-month quarterly average of -$3.06M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.37M-80.2% QoQ
Last fiscal yearDec 2025
$1.14M-70.4% YoY
LTMMar 2026
-$12.25M-136.7% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-111.4%——
1 year-70.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
1.14M USD
Year-over-year change
-70.4%

Net Change in Cash vs competitors

How BBNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -136.7% is the 5th highest of 7, against a peer median of -10.6%.
  • Net change in cash amounts to 11.1% of revenue for BBNX, versus a peer median of 7.0%.
BBNX Competitors
Net Change in Cash for BBNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 26.05B DKK+175.7%+77.5%7.9%
PODDInsulet CorporationLTM Jun 2026$586.7M USD-295.2%+26.7%19.2%
MMEDMiniMed Group, Inc. Common StockLTM Jul 2026$198M USD——6.1%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026$125.75M USD+2426.6%-40.4%12.2%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$61.31M USD-209.6%-38.7%—
DXCMDexCom, Inc.LTM Jun 2026$55.1M USD-124.9%—1.1%
BBNXBeta Bionics, Inc.LTM Mar 2026$12.25M USD-136.7%—11.1%
MNKDMannKind CorporationLTM Mar 2026$5.53M USD+103.8%—1.5%
Peer median (excluding BBNX) —-10.6%-6.0%7.0%

Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(64.75M)(44.1M)(54.76M)(73.2M)
Depreciation & Amortization2.09M2.09M2.28M2.88M
Deferred Income Tax0000
Stock-Based Compensation6.1M5.66M6.38M16.38M
Change in Working Capital(2.79M)(6.36M)(12.15M)(8.99M)
Accounts Receivables0(4.49M)(7.62M)(5.16M)
Inventory0(1.19M)(11.44M)(9.88M)
Accounts Payables(77K)716K1.52M2.1M
Other Working Capital(2.71M)(682K)5.39M3.95M
Other Non-Cash Items(854K)10.27M9.96M12.01M
Operating Cash Flow(60.21M)(32.45M)(48.27M)(50.93M)
Capital Expenditures(772K)(402K)(3.4M)(5.3M)
Acquisitions (Net)0000
Purchases of Investments0(69.3M)(72.13M)(327.51M)
Sales of Investments0072M170M
Other Investing Activities3K(69.29M)50K0
Investing Cash Flow(769K)(69.69M)(3.48M)(162.81M)
Debt Repayment0000
Common Stock Issued389K29K55.62M214.87M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities389K101.03M00
Financing Cash Flow56.78M101.03M55.62M214.87M
Effect of Forex Changes0000
Net Change in Cash(4.2M)(1.11M)3.87M1.14M
Free Cash Flow(60.98M)(32.85M)(51.67M)(56.22M)

Beta Bionics, Inc.

NASDAQ:BBNX

Intrinsic Alpha fair value

Locked

Current Price

$14.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.